Resources Repository
-
ArticlePublication 2019Cost-Effectiveness of U.S. National SSB Tax with a Multistakeholder Approach: Who Pays and Who Benefits
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) …
This analysis estimated the health impact and cost-effectiveness of a national penny-per-ounce sugar-sweetened beverage (SSB) tax, overall and with stratified costs and benefits for nine distinct stakeholder groups. A microsimulation model (CVD PREDICT) was used to estimate cardiovascular disease reductions, quality-adjusted life years gained, and cost-effectiveness for U.S. adults aged 35 to 85 years, evaluating full and partial consumer price pass-through. Results showed that from both a health care and societal perspective, the SSB tax was…
Microsimulation | Government/Law | North America | Policy/Regulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Business/Industry | Economics/Finance | Health/Medicine -
ArticlePublication 2019Health Impact and Cost-Effectiveness of SSB Taxes for Reducing Cancer Burden in the U.S.
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) …
This analysis evaluated the health outcomes, costs, and cost-effectiveness of a national sugar-sweetened beverage (SSB) tax policy for reducing obesity-related cancer in the U.S. A probabilistic cohort state-transition model, the Diet Cancer Outcome Model (DiCOM), was used to project the effect of a national $0.01 per ounce SSB excise tax on 13 obesity-associated cancers among U.S. adults age 20 and older over their lifetime. Cost-effectiveness was evaluated using both government affordability and societal perspectives. Results showed…
Microsimulation | Government/Law | North America | Policy/Regulation | Mathematical Models | Cost-Effectiveness Analysis | Chronic Disease/Risk | Economics/Finance | Health/Medicine -
ArticlePublication 2018Cost-Effectiveness of Financial Incentives and Disincentives for Improving Food Purchases and Health through SNAP
This analysis estimated the health impact, costs, and cost-effectiveness of food incentives, disincentives, or restrictions …
This analysis estimated the health impact, costs, and cost-effectiveness of food incentives, disincentives, or restrictions in the Supplemental Nutrition Assistance Program (SNAP). A microsimulation model (CVD-PREDICT) was used to compare three policy interventions: (1) a 30% incentive for fruits and vegetables (F&V), (2) a 30% F&V incentive with a restriction of sugar-sweetened beverages (SSBs), and (3) a broader incentive/disincentive program for multiple foods that also preserves choice (SNAP-plus). From a societal perspective, all three scenarios…
Microsimulation | Government/Law | North America | Policy/Regulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Business/Industry | Economics/Finance | Health/Medicine -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | Government/Law | North America | Policy/Regulation | Preferences/Values | Costing Methods | Chronic Disease/Risk | Mental Health | Economics/Finance | Health/Medicine -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Government/Law | North America | Policy/Regulation | Costing Methods | Chronic Disease/Risk | Health/Medicine -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Technology Assessment | Government/Law | North America | Policy/Regulation | Costing Methods | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Health/Medicine | Science/Technology -
Resource PackPublication, Teaching Resource 2017Resource Pack: U.S. Opioid Epidemic
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public …
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public health crisis, requiring an urgent coordinated response and innovative scientific solutions. This resource pack was curated for educators and students interested in how decision analytic methods and tools can be applied to the problem of opioid addiction.
Evidence Synthesis | Government/Law | North America | Policy/Regulation | Preferences/Values | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Economics/Finance | Health/Medicine | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
Lesson/ModuleWeb Portal, Teaching Resource 2016Scientific Evidence of Factual Causation
This module examines three scientific areas that provide evidence bearing on causation in the “toxic …
This module examines three scientific areas that provide evidence bearing on causation in the “toxic tort” or environmental disease context: epidemiology, toxicology, and genetics. These scientific disciplines are used in civil lawsuits and in regulatory proceedings in which causation or risk is an issue. The module is appropriate for non-scientist law students as well as others interested in learning the science of toxic tort causation, including practicing attorneys, judges, and public policy and public health…
Evidence Synthesis | Government/Law | North America | Policy/Regulation | Risk Analysis | Child/Nutrition | Chronic Disease/Risk | Environmental Health | Climate/Environment | Food/Agriculture | Health/Medicine | Science/Technology | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Quantitative Literacy -
Lesson/ModuleWeb Portal, Teaching Resource 2016Placing a Bet: New Therapy for Parkinson's Disease
This module is intended for use by business school students. It examines the decision-making process …
This module is intended for use by business school students. It examines the decision-making process at a pharmaceutical company as its chief operating officer decides whether to invest in the development and licensing of a promising treatment for Parkinson’s disease. The module is structured around a drug development case that provides students with opportunities to: (1) analyze a rich and realistic description of the complex scientific and medical results associated with a promising therapeutic molecule…
Test Performance | Technology Assessment | Government/Law | North America | Policy/Regulation | Chronic Disease/Risk | Business/Industry | Health/Medicine | Science/Technology | Global | College | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy